Tag Archives: finance

Investor Panels at RESI Boston September

26 Aug

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Life Science Nation (LSN) team is preparing to welcome the global life science ecosystem to Boston for the upcoming RESI conference this September. With an engaging lineup of investor panels, workshops, and the Innovator’s Pitch Challenge, founders and CEOs will have the opportunity to connect directly with investors while gaining tactical insights into fundraising and partnership strategies.

The RESI Boston program features seven investor panels spanning impact investing, mental health, oncology, diagnostics, family offices, corporate venture capital, and big pharma partnerships. These panels bring together a diverse group of experts—from venture funds and strategic investors to philanthropic groups and family offices—each offering unique perspectives on how they evaluate life science and healthcare opportunities.

Each 50-minute session will provide a candid look at what drives investor interest in early-stage ventures, what makes a company stand out in competitive landscapes, and how founders can build lasting relationships with the capital sources they need.

RESI Boston is not just about learning—it’s about engagement. Panelists will share their perspectives on industry landscapes, while also fielding questions and offering insights that directly address the challenges entrepreneurs face. These conversations are intended to bridge the gap between companies and capital providers, fostering the connections that fuel healthcare innovation.

Below is the schedule of investor panels at RESI Boston this September:

John-Abeles
John Abeles
General Partner
Northlea Partners 		Marc-Appel
Marc Appel
Managing Partner
Pacific Bridge NY 		Jonathan-Behr
Jonathan Behr
Partner
Dementia Discovery Fund
David Berry
David Berry
Managing Partner
Averin Capital 		Hyelim-Cho
Hyelim Cho
Sr. Director, BD and Alliance Management
RayzeBio
(a Bristol Myers Squibb company) 		Alex-de-Winter
Alex de Winter
Vice President of New Ventures
Danaher Corporation
Yizhen-Dong
Yizhen Dong
Managing Partner
Raise Health 		David-Fogel
David Fogel
Member of Screening & Due Diligence Committees
Mass Medical Angels 		Eric-Furfine
Eric Furfine
CEO & CSO
Mosaic Biosciences
Navin-Govind
Navin Govind
Partner
Evidence Ventures 		Andres-Hurtado-Lorenzo
Andres Hurtado-Lorenzo
SVP, Translational Research & IBD Ventures
Crohn's and Colitis Foundation 		Anula Jayasuriya
Anula Jayasuriya
Co-Founder and Partner
Kidron Capital
Arianne Kidder
Arianne Kidder
Partner
Seae Ventures 		Claire-Leurent
Claire Leurent
Managing Director
AbbVie Ventures 		Ron-Levin
Ron Levin
Managing Partner
Alumni Ventures
Vivian-Li
Vivian Li
Investor
K2 Venture Partners 		Michael Loftus
Michael Loftus
Director
PoC Capital 		Nune-Martiros
Nune Martiros
Senior Associate
Paladin Capital Group
Jeffrey-Moore
Jeffrey Moore
President
MP Healthcare Venture Management (MPH) 		Chris Murray
Chris Murray
Principal
MVM Life Science Partners 		Nikhil Mutyal
Nikhil Mutyal
Head of Search and Evaluation, Respiratory and Immunology
AstraZeneca
Komeil-Nasrollahi
Komeil Nasrollahi
Sr. Director Innovation & Venture Partnerships
Siemens Healthineers 		Stephanie Oestreich
Stephanie Oestreich
Managing Director
Myeloma Investment Fund 		Armin-Rump
Armin Rump
Director of Global BD
Otsuka Pharmaceutical Co., Ltd.
Jeremy-Sohn
Jeremy Sohn
Managing Partner
P74 Ventures 		Mike-Thomas
Mike Thomas
Managing Partner
Bold Brain Capital 		John-Tremblay
John Tremblay
Investor
Launchpad Venture Group
Chensu-Wang
Chensu Wang
Investment Manager
Yonjin Venture 		Jenny-Wang
Jenny Wang
Director, Search & Evaluation, Oncology
AbbVie 		Tyler-Wanke
Tyler Wanke
Investor
Wanke Family Office

Whether you are developing novel therapeutics, diagnostics, medical devices, or digital health solutions, the investor panels at RESI Boston will deliver the knowledge and networking opportunities to help you advance your fundraising journey.

Tags: , , , , ,

Navigating the FDA: Why Early Strategic Planning is Critical   

26 Aug

By Claire Davies, Shareholder, Polsinelli (Special Guest Contributor)

claire-davies

Life sciences companies are constantly innovating with the goal of developing groundbreaking medical products. Unfortunately, the most novel products often face more uncertainty about their regulatory pathway to market—with several factors heightening that uncertainty today. These include the loss of many FDA policy and scientific staff over the past six months and multiple changes in leadership, such as at the head of the agency’s drug and biologics programs. Although significant personnel change may present opportunities for companies that would benefit from a change in the agency’s historic regulatory approach, it also unsettles precedent for the FDA’s expectations. In addition, as numerous companies explore applications of generative AI, the agency itself has indicated that generative AI-enabled products present challenges to existing (often decades old) laws that govern FDA’s regulatory framework.

With these factors in play, companies may be tempted to hold off on spending resources to map out their regulatory strategy and get feedback from the agency. But incorporating regulatory considerations into early business plans remains key for a number of reasons:

  • Efficient Product Development: Whether and how FDA will regulate your product determines the level of evidence and type of application needed to enter the market. (Does your AI-enabled product fall within an exception from regulation as a medical device? If not, it may require an FDA application supported by significant data.) An early understanding of the regulatory pathway can help companies budget development costs more accurately. It can also help them anticipate and proactively address regulatory hurdles, ultimately shortening the time it takes to get the product to market.
  • Raising capital: Regardless of scientific promise, companies that underestimate the regulatory complexity of getting a medical product to market or that lack an experienced in-house or external advisory team in this area may be viewed as a risky proposition for investors. In contrast, a thorough understanding of the regulatory pathway and plan for navigating the challenges to commercialization can help distinguish a company from the crowd.

Ultimately, an early and proactive approach to your regulatory strategy is a critical investment that can help shorten time to market and increase your company’s attractiveness to investors.

Claire Davies is a Shareholder in Polsinelli’s FDA practice where she provides strategic counsel to help clients navigate FDA regulatory and compliance challenges. Claire has handled a wide range of issues involving medical devices, biological products, drugs and human cells, tissues and cellular and tissue-based products (HCT/Ps). Prior to joining Polsinelli, Claire spent nearly a decade as an attorney in the FDA’s Office of the Chief Counsel. Her work at FDA often involved advising agency leadership on high-profile and significant matters, such as responses to emerging public health threats and user fee negotiations with industry.

About Polsinelli

Polsinelli is an Am Law 100 firm with more than 1,200 attorneys in over 25 offices nationwide. Recognized as one of the top firms for excellent client service and client relationships, Polsinelli is committed to meeting our clients’ expectations of what a law firm should be. Our attorneys provide value through practical legal counsel infused with business insight, offering comprehensive corporate, transactional, litigation and regulatory services with a focus on health care, real estate, finance, technology, private equity and life sciences. Polsinelli PC, Polsinelli LLP in California, Polsinelli PC (Inc) in Florida.

Tags: , , , , , , , , ,

Impact Investors & Venture Philanthropy Panel 

19 Aug

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

As healthcare innovation continues to accelerate, the role of impact investors and venture philanthropists has become increasingly vital. These funders are not only focused on financial returns but also on advancing health equity, improving patient outcomes, and addressing pressing unmet needs across the life science ecosystem.

At RESI Boston this September, the Impact Investors & Venture Philanthropy Panel will spotlight how this unique group of investors deploys capital to drive meaningful change in healthcare. Panelists will share their perspectives on how they define and measure impact, what differentiates their investment approach from traditional venture capital, and how they partner with founders to align their mission with milestone-driven growth. Attendees will gain a deeper understanding of how these organizations catalyze innovation in areas often overlooked by mainstream funding.

This discussion will feature:

David-Fogel Jonathan-Behr Andres-Hurtado-Lorenzo
David Fogel
Member of Screening & Due Diligence Committees
Mass Medical Angels
(Moderator)		 Jonathan Behr
Partner
Dementia Discovery Fund		 Andres Hurtado-Lorenzo
SVP, Translational Research & IBD Ventures
Crohn’s and Colitis Foundation
Ron-Levin Stephanie-Oestreich
Ron Levin
Managing Partner
Alumni Ventures		 Stephanie Oestreich
Managing Director
Myeloma Investment Fund

The panel will highlight strategies that are shaping a more inclusive and outcomes-focused future for healthcare through impact-driven investing.

Register today to join this discussion and connect with investors, entrepreneurs, and innovators at RESI Boston.

Tags: , , , , ,

Hot Investor Mandate: Cross-Border VC Firm Invests $10-20M in Early-Stage Therapeutics and Later-Stage Medical Devices in US and China 

19 Aug

A Beijing-based venture capital investor with offices across China and Hong Kong manages $8 billion USD in assets and is currently overseeing multiple funds, including RMB and USD funds. The firm invests across various sectors, with life sciences and healthcare being one of the major focus areas. The firm is capable of investing from early seed to pre-IPO. For early-stage investments, the sweet spot is from Seed to Series B, with average check sizes ranging from $10 million to $20 million USD. Follow-on investments are possible. The firm is open to both leading and co-investing and will consider board or observer seats on a case-by-case basis. In terms of geographic focus, the firm primarily targets opportunities based in the United States and China. 

The firm is most interested in biotech therapeutics or drugs and is open to various modalities such as cell therapies, antibodies, small molecules, and more. The firm is open to considering different indications, with preferences for solid tumors and autoimmune diseases. It prefers assets that are close to the IND phase or, at the very least, have obtained partial proof of concept. The firm is also open to considering medical instruments but typically focuses on companies at a later stage, generating revenue or profits. 

The firm does not have specific requirements for management teams but prefers teams with strong backgrounds and successful track records. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: USA-Based Seed Fund Invests in Software-Enabled Health Technologies, With Expanding Interests in Traditional Life Science Companies 

19 Aug

A US-based advisory group also manages a seed fund making investments into healthcare companies. Traditionally, the firm has strong expertise in enterprise software and is most interested in healthcare companies that have a software component (such as EHR/EMR integration), monitoring technologies, and early-stage detection devices and diagnostics. The firm is also starting to explore opportunities in traditional biotech investments and drug discovery-enabling tools. The firm considers global opportunities. 

The firm is currently exploring opportunities in traditional life sciences (therapeutics, diagnostics) as well as software or technology-enabled healthcare companies. While the firm is opportunistic regarding specific technologies and disease areas, the firm generally does not invest in companies that require FDA regulatory approval. 

The firm does not have specific company or management team requirements and has no preference on leading or co-investing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Cross-Border Investment Firm Seeks Therapeutics and Medical Technologies, Investing from Seed to Pre-IPO

19 Aug

The firm is an investment firm based in Shanghai, China. The firm manages 30 billion RMB and invests in fund of funds as well as direct equity investments. The firm invests across multiple sectors, with life science and healthcare being one of its primary focuses. The sweet spot starts from pre-A rounds, and the firm can invest anywhere up to pre-IPO stages. While the firm primarily focuses on opportunities in China, it is open to global opportunities, particularly those interested in soft-landing in China/Shanghai or with a China angle. The firm is open to both leading investments and co-investing. 

Within life science and healthcare, the firm is most interested in biotech therapeutics and medical technologies. For therapeutics, the firm is open to exploring various modalities (excluding mRNA) and indications such as CNS and oncology. For medical devices, the firm seeks innovative technologies, including invasive technologies, imaging devices, and brain-computer interfaces, rather than non-innovative solutions such as consumables. 

The firm does not have specific requirements for a company’s founding team but prefers companies interested in coming to Shanghai/China. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Multi-Stage Generalist Seed Fund Invests Globally in Value-Based Life Sciences and Healthcare Companies

19 Aug

A multi-stage generalist venture capital investor can write flexible check sizes typically up to $300,000 for early-stage opportunities and can participate in follow-on investments. The firm is open to global companies. 

The firm has invested in digital health, techbio, value-based healthcare, and life sciences. The firm is disease-agnostic. Notable investments in healthcare have included digital health platforms, pharmacy solutions, clinical trial innovation, and biotech companies. 

The firm does not have specific company or management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →